



NON-INSURED HEALTH BENEFITS PROGRAM: COVERAGE OF NALOXONE NASAL SPRAY

Effective March 27, Narcan Nasal Spray (DIN 02458187) is an open benefit for clients of the NIHB Program.

Narcan Nasal spray contains naloxone, used to treat opioid overdose. Narcan Nasal Spray has been added to NIHB's Pharmacist-Initiated Treatment Policy meaning it is eligible for reimbursement when prescribed or recommended by a pharmacist. It may be requested for client's personal use, or to protect an at-risk person. The client requesting naloxone does not have to specify who it is for; however, it must be billed to the NIHB Program under the name of the eligible client who is requesting it (even if it is not for their personal use).

Where pharmacies are providing ancillary supplies to support safe nasal naloxone administration and overdose management, providers can bill the cost of the naloxone and ancillary supplies as a naloxone nasal spray kit under pseudo-DIN 09991475. Accepted contents for reimbursement in a naloxone nasal spray kit include:

- 2 x 4 mg naloxone nasal spray devices
- 1 rescue breathing mask
- 1 pair of gloves
- Carrying case

The ancillary items should not be billed separately from the naloxone nasal spray. Please note that all claims are subject to audit verification.

Injectable naloxone kits continue to be an open benefit under NIHB.

Naloxone kits and training may also be available through local or regional public health services.

Health Canada encourages those at risk of an opioid overdose, and people close to them, to have a naloxone kit and the training to use it.